Investor Relations

Investor Relations

Latest News View All News

Nov 17, 2017 • 8:30 AM EST

Cerecor Announces Leadership Changes

Nov 17, 2017 • 8:15 AM EST

Cerecor Acquires TRx Pharmaceuticals

Nov 6, 2017 • 8:15 AM EST

Cerecor Inc. Reports Third Quarter 2017 Financial Results

Stock Information View Detailed Stock Information

NASDAQ: CERC Cerecor, Inc.
Price
Change
Volume
Day Range
52 Week Range

Company Overview

Cerecor is a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders. Cerecor's lead drug candidate is CERC-301, which Cerecor currently intends to explore as a novel treatment for orphan neurological indications.